Russell Investments Group Ltd. lifted its position in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 67.9% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 129,000 shares of the biopharmaceutical company’s stock after buying an additional 52,148 shares during the quarter. Russell Investments Group Ltd. owned about 0.20% of Portola Pharmaceuticals worth $4,872,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Portola Pharmaceuticals in the first quarter valued at about $128,000. Mackay Shields LLC purchased a new stake in shares of Portola Pharmaceuticals in the first quarter valued at about $660,000. Trexquant Investment LP purchased a new stake in shares of Portola Pharmaceuticals in the first quarter valued at about $482,000. American Century Companies Inc. raised its holdings in shares of Portola Pharmaceuticals by 22.5% in the first quarter. American Century Companies Inc. now owns 74,315 shares of the biopharmaceutical company’s stock valued at $2,427,000 after buying an additional 13,667 shares during the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of Portola Pharmaceuticals by 11.1% in the first quarter. Prudential Financial Inc. now owns 128,822 shares of the biopharmaceutical company’s stock valued at $4,208,000 after buying an additional 12,826 shares during the last quarter. 94.26% of the stock is owned by institutional investors.
A number of equities research analysts have recently commented on PTLA shares. ValuEngine raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, May 29th. Oppenheimer set a $80.00 target price on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 5th. Zacks Investment Research cut shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. Cowen reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a report on Thursday, August 9th. Finally, Credit Suisse Group reaffirmed an “underperform” rating and issued a $28.00 target price (down from $49.00) on shares of Portola Pharmaceuticals in a report on Friday, August 10th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $52.17.
NASDAQ PTLA opened at $29.37 on Friday. Portola Pharmaceuticals Inc has a 52-week low of $24.63 and a 52-week high of $56.91. The company has a debt-to-equity ratio of 0.91, a quick ratio of 6.59 and a current ratio of 6.69.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.12). The firm had revenue of $4.01 million for the quarter, compared to analysts’ expectations of $6.35 million. Portola Pharmaceuticals had a negative return on equity of 111.64% and a negative net margin of 1,503.29%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned ($1.22) earnings per share. sell-side analysts expect that Portola Pharmaceuticals Inc will post -5.77 EPS for the current fiscal year.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Read More: Fiduciary
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.